HFBL - Home Federal Bancorp Of Louisiana Profile, Stock Quotes, Financial Analysis, Charts, Fundamentals

Home Federal Bancorp, Inc. Of Louisiana
Home Federal Bancorp, Inc. of Louisiana, a Louisiana chartered corporation, became the holding company for Home Federal Bank ("Home Federal Bank" or the "Bank") on December 22, 2010, upon completion of the Bank's second step conversion from the mutual holding company form of organization to the stock holding company form of organization. As part of the conversion, all outstanding shares of the former Home Federal Bancorp, Inc. of Louisiana common stock (other than those owned by Home Federal Mutual Holding Company) were converted into the right to receive 0.9110 of a share, and cash in lieu of fractional shares, of Home Federal Bancorp common stock resulting in approximately 1,100,609 shares issued in the exchange. In addition, a total of 1,945,220 shares of common stock of Home Federal Bancorp were sold in subscription, community and syndicated community offerings to certain depositors and borrowers of the Bank, the Bank's Employee Stock Ownership Plan and other investors for $10.00 per share, or $19.5 million in the aggregate. Treasury stock held was cancelled. The net proceeds of the offering were approximately $18.0 million, after offering expenses.

Luckwel Pharmaceuticals Inc announced third quarter operating shortfall of $-0.134045 millions

In the third quarter Luckwel Pharmaceuticals Inc reached break-even of $-0.00 per share compare to $-0.01 a year ago and from $-0.00 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.00 millions in the same quarter a year ago and sequentially from $0.00 millions.

Losses Widen but Revenues Unchanged

In the third quarter Tauriga Sciences, Inc increased losses of $-0.02 per share compare to $-0.01 a year ago and increased losses from $-0.01 per share from the previous quarter.

Sales remained unchanged to $0.09 millions from $0.00 millions in the same quarter a year ago and sequentially Sales improved by 25.9 % from $0.07 millions.

Sangui Biotech International Inc announced second quarter operating shortfall of $-0.036533 millions

In the second quarter Sangui Biotech International Inc reached break-even of $0.00 per share compare to $0.00 a year ago and from $0.00 per share from the previous quarter.

Sales fell sharply by -73.5 % to $0.01 millions from $0.04 millions in the same quarter a year ago and sequentially from $0.00 millions.

Tweet
Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar WSR's Profile Stock Price WSR's Financials Business Description Fundamentals Charts & Quotes WSR's News Suppliers WSR's Competitors Customers & Markets Economic Indicators WSR's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

HFBL Company Profile

Duo World Inc announced third quarter operating shortfall of $-0.00183 millions

Luckwel Pharmaceuticals Inc announced third quarter operating shortfall of $-0.134045 millions

Losses Widen but Revenues Unchanged

Earnings helped by tax benefit

Sangui Biotech International Inc announced second quarter operating shortfall of $-0.036533 millions